Skip to main content

Advertisement

Table 2 Relative risk of COPD exacerbations stratified by severity in patients randomised to fluticasone and placebo groups over one year.

From: Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial

  COPD exacerbations Relative risk of COPD exacerbation for patients randomised to placebo or fluticasone (n = 260)
  Fluticasone (n = 128) Placebo (n = 132) Mean days of patient exposure Exacerbation grouping Incidence rate ratio 95% confidence interval adjusted p-value
Exacerbations while in trial Unreported 129 Unreported 116 235 in fluticasone, 179 in placebo All 1.11 0.91 1.36 0.298
  Moderate 224 Moderate 276       
  Severe 21 Severe 22   Moderate and severe only 1.25 0.96 1.58 0.067
  Total 373 Total 413       
Exacerbations while on randomised treatment Unreported 112 Unreported 99 371 in both groups All 1.48 1.17 1.86 0.001
  Moderate 158 Moderate 182       
  Severe 9 Severe 12   Moderate and severe only 1.63 1.23 2.17 0.001
  Total 279 Total 293